Sino Biopharmaceutical Limited (HKG: 1177) announced that TQ‑A3334 (a Toll-like receptor 7 agonist) and TQA3605 (a core protein allosteric modulator, CpAM), both Category 1 innovative drugs independently developed by its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), have been included in the Breakthrough Therapy Designation Program by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The two assets respectively address two major unmet needs in chronic hepatitis B (CHB) treatment: functional cure and low-level viremia (LLV).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE of NMPA (China) |
| Designation | Breakthrough Therapy Designation Program |
| Products | TQ‑A3334 (oral TLR7 agonist); TQA3605 (CpAM) |
| Drug Category | Category 1 innovative drugs, independently developed by CTTQ |
| Target Needs | Functional cure of CHB (TQ‑A3334); low-level viremia (TQA3605) |
| Clinical Stage | TQ‑A3334: Phase III initiated; TQA3605: Phase II completed |
| Announcement Date | 27 Oct 2026 |
Drug Profiles & Mechanisms of Action
- TQ‑A3334 (TLR7 Agonist): An orally administered, highly selective Toll-like receptor 7 agonist that activates innate and adaptive immune pathways, inducing interferon and cytokine responses to reshape the body’s immune response against hepatitis B virus (HBV) — complementing the direct antiviral effects of nucleos(t)ide analogues (NAs). Its immune-rewiring approach targets the functional cure goal that NAs alone cannot achieve.
- TQ‑A3334 Clinical Status: Has achieved improvements in key efficacy endpoints in Phase II studies and has initiated Phase III clinical trials.
- TQA3605 (CpAM): A core protein allosteric modulator that targets hepatitis B core antigen (HBcAg) and blocks viral nucleocapsid formation, effectively inhibiting HBV replication across multiple genotypes. It shows no cross-resistance with standard-of-care NAs and can indirectly affect the stability of the covalently closed circular DNA (cccDNA) pool, with a relatively high resistance barrier — positioning it against persistent low-level viremia.
- Therapeutic Context: NAs suppress HBV DNA but rarely eliminate the viral reservoir; LLV and the absence of functional cure remain the field’s defining unmet needs, driving global interest in immunomodulatory and capsid-targeting add-ons.
Clinical Evidence – TQA3605 Phase II Results
| Endpoint | Result | Comparator | Significance |
|---|---|---|---|
| HBV DNA < LLOQ (<20 IU/mL) at Week 24 | Response rates approaching 90% in all treatment groups (TQA3605 + NAs) | NA monotherapy control group | p<0.0001 — statistically superior |
The Phase II study demonstrated that TQA3605 in combination with NAs significantly increased the proportion of subjects achieving HBV DNA below the lower limit of quantification at Week 24, with response rates near 90% across all treatment groups — superior to NA monotherapy. Additional Phase II data for TQ‑A3334 were not disclosed beyond improvement in key efficacy endpoints.
Market Impact & Outlook
- Dual BTD Advantage: Simultaneous Breakthrough Therapy Designations for two complementary assets may accelerate CDE review timelines and signal regulatory confidence in CTTQ’s HBV franchise.
- Complementary Modalities: A TLR7-mediated immune activator plus a capsid assembly blocker attacking different nodes of the HBV life cycle positions CTTQ to build combination regimens aimed at functional cure — the holy grail of CHB therapy.
- China CHB Burden: China carries one of the world’s largest CHB populations, with tens of millions on long-term NA therapy; a differentiated add-on addressing LLV carries substantial domestic commercial potential.
- Global Competitive Context: The CpAM and TLR7 classes are contested internationally; no CpAM has yet been approved in China, leaving TQA3605 with potential first-mover domestic positioning.
- Pipeline Momentum: With TQ‑A3334 already in Phase III, CTTQ’s HBV program is among the most advanced innovative portfolios in China’s antiviral landscape.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding TQ‑A3334 and TQA3605, including Phase III execution, potential functional-cure outcomes, and regulatory pathways under Breakthrough Therapy Designation. Designation does not guarantee approval; actual results may differ due to risks including clinical trial outcomes, safety findings, regulatory review decisions, and competitive dynamics in chronic hepatitis B therapy.-Fineline Info & Tech
